4.6 Article

Efficacy and safety analysis of TACE plus Donafenib plus Toripalimab versus TACE plus Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients

Caihua Zhu et al.

Summary: Neoadjuvant TACE plus PD-1 inhibitor achieves a satisfactory downstaging rate, acceptable survival profile, and tolerance in intermediate-stage HCC patients.

IRISH JOURNAL OF MEDICAL SCIENCE (2023)

Article Pharmacology & Pharmacy

Donafenib in hepatocellular carcinoma

Rusi Chen et al.

Summary: Hepatocellular carcinoma (HCC) is a global healthcare problem, with a high prevalence in nonindustrialized countries and a rising incidence in industrialized countries. Sorafenib, the first therapeutic agent for unresectable HCC, demonstrated efficacy in 2007. However, the tolerability of these drugs remains an unresolved issue. Donafenib, a deuterated form of sorafenib, has shown better overall survival and favorable safety and tolerability in a clinical trial, leading to its approval as a possible first-line treatment for unresectable HCC by the National Medical Products Administration of China in 2021.

DRUGS OF TODAY (2023)

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Transarterial chemoembolization for hepatocellular carcinoma with vascular invasion

Shiro Miyayama et al.

Summary: Although global guidelines only recommend systemic therapy for hepatocellular carcinoma with vascular invasion, various treatments including transarterial chemoembolization (TACE) are frequently performed. However, standard techniques for TACE have not been established. TACE is commonly used for tumors invading the portal vein, hepatic vein, and bile duct.

BRITISH JOURNAL OF RADIOLOGY (2022)

Review Pharmacology & Pharmacy

Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress

Zachary J. Brown et al.

Summary: Unfortunately, some HCC patients are not eligible for curative treatments, making locoregional treatments like TACE crucial. Systemic therapy has advanced in the past decade, with combination atezolizumab and bevacizumab now the standard for advanced disease. Combination therapies with TACE, including systemic therapies, locoregional therapies, and immunotherapies, show promise for the management of intermediate stage HCC.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Review Immunology

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China

Lin Zhang et al.

Summary: Toripalimab, a selective anti-PD-1 monoclonal antibody, has shown anti-tumor effects in melanoma, nasopharyngeal carcinoma, and urothelial carcinoma, and could be a valuable choice for future tumor treatment decision-making.

FRONTIERS IN IMMUNOLOGY (2022)

Article Gastroenterology & Hepatology

Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study

Yashwant Patidar et al.

Summary: The combination of TACE with sorafenib showed better outcomes in terms of disease control rate, time to progression, and overall survival compared to TACE alone in treating advanced-stage hepatocellular carcinoma.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma

Yan-Jun Xiang et al.

Summary: This study compares the efficacy of TACE combined with a PD-1 inhibitor and TACE combined with a PD-1 inhibitor and lenvatinib for hepatocellular carcinoma (HCC) patients. The results show that the triple therapy group had significantly better outcomes in terms of PFS, OS, ORR, and DCR compared to the doublet therapy group, with manageable safety.

HEPATOLOGY RESEARCH (2022)

Article Immunology

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study

Mingyue Cai et al.

Summary: TACE-L-P significantly improves survival in advanced HCC patients with acceptable safety, especially in those without main portal vein invasion but with extrahepatic metastasis or tumor number >3.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study

Shuping Qu et al.

Summary: This study compared the efficacy and safety of a combination therapy of transcatheter arterial chemoembolization (TACE), Lenvatinib, and programmed cell death protein-1 (PD-1) inhibitors with TACE alone in patients with unresectable hepatocellular carcinoma (uHCC). The combination therapy showed higher tumor response rate, longer progression-free survival, and overall survival compared to TACE alone. The neutrophil-to-lymphocyte ratio was identified as an independent factor affecting survival.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study

Ziqiang Han et al.

Summary: This retrospective study investigated the prognostic effect and prognostic factors of transcatheter arterial chemoembolization (TACE) plus tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICIs) in the treatment of unresectable hepatocellular cancer (uHCC). The study found that TACE+TKI+ICIs therapy can prolong overall survival (OS) and improve prognosis effectively, with a well-characterized safety profile.

FRONTIERS IN ONCOLOGY (2022)

Article Gastroenterology & Hepatology

Assessment of efficacy and prognostic factors by Gelfoam for DEB-TACE in unresectable large hepatocellular carcinoma with portal vein tumor thrombus: a multi-center retrospective study

Guang Sheng Zhao et al.

Summary: This study aimed to investigate the clinical efficacy and prognostic factors of Gelfoam for drug-eluting bead transarterial chemoembolization (GMD-TACE) in patients with unresectable large hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). The results showed that GMD-TACE can be used as a core treatment for improving the quality of life and extending the median overall survival (OS) in these patients. The type of tumor thrombus and combination therapy were identified as important factors affecting prognosis.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Oncology

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study

Brett Marinelli et al.

Summary: In this study, we evaluated the safety and efficacy of combining immune checkpoint inhibitors (ICIs) with transarterial chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma. The results showed that patients in the multimodal treatment group had a longer progression-free survival (PFS) and a numerically longer overall survival (OS) compared to the monotherapy group. In addition, the multimodal treatment group had fewer adverse events (AEs) and TACE did not significantly affect liver function. This study suggests that combining TACE with ICI may be a feasible and effective treatment option for selected patients with advanced hepatocellular carcinoma.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial

ZhiCheng Lai et al.

Summary: In this study, we investigated the efficacy, safety, and predictive biomarkers of lenvatinib, toripalimab, and FOLFOX-HAIC combination therapy as a first-line treatment for high-risk advanced hepatocellular carcinoma (HCC). The results showed encouraging antitumour activity with a progression-free survival rate of 80.6% at six months. Adverse events were common, and the levels of CCL28 and BTC may predict the efficacy of the combination therapy.

EUROPEAN JOURNAL OF CANCER (2022)

Article Surgery

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

Wei-Feng Qu et al.

Summary: This study evaluated the conversion rate and clinical outcomes of a first-line combination therapy of lenvatinib, transarterial chemoembolization, and immunotherapy for initially unresectable hepatocellular carcinoma (uHCC). The results showed that the triple combination therapy (t-CT) had better treatment responses and conversion rate compared to the dual combination therapy (d-CT). The neoadjuvant t-CT regimen is recommended for patients with macrovascular invasion.

BJS OPEN (2022)

Article Cell Biology

Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma

Ahmed Montasser et al.

Summary: This study evaluated the impact of transarterial chemoembolization (TACE) on programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in surgically treated hepatocellular carcinomas (HCCs). The results showed that TACE treatment led to increased levels of PD-1 and PD-L1 expression in HCCs, supporting the potential use of TACE in combination with immunotherapy to enhance tumor response in selected cases.

HISTOPATHOLOGY (2021)

Article Pharmacology & Pharmacy

Donafenib: First Approval

Susan J. Keam et al.

Summary: Donafenib is an oral multikinase inhibitor developed by Suzhou Zelgen Biopharmaceuticals Co., Ltd. for the treatment of various cancers, including hepatocellular carcinoma. It recently received its first approval in China for unresectable hepatocellular carcinoma, marking a significant milestone in its development.
Article Gastroenterology & Hepatology

Current epidemiology in hepatocellular carcinoma

Peter Konyn et al.

Summary: This review discusses the risk factors, global trends, and high incidence rates of HCC in Asia and Africa. Interventions to minimize the global burden of HCC include reducing common risk factors, treating underlying causes effectively, and implementing comprehensive screening programs for HCC. Healthcare inequity is identified as a crucial area for improvement in addressing disparities in HCC incidence and mortality among racial and ethnic minorities in multiethnic countries.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Article Oncology

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world

Diyang Xie et al.

Summary: The study showed that the combination therapy of PD-1 inhibitor sintilimab with TKIs demonstrated promising efficacy and tolerable toxicity in patients with unresectable HCC. Addition of TACE to systemic therapies also resulted in favorable tumor control and safety. Select patients may benefit from surgical resection as a radical treatment option.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

Article Oncology

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin et al.

Summary: This study demonstrated that donafenib is more effective than sorafenib in treating advanced hepatocellular carcinoma, showing promise in improving patients' survival outcomes, and exhibiting favorable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Biochemistry & Molecular Biology

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai et al.

Summary: The study is a double-blind phase 3 trial that shows the combination of toripalimab with GP chemotherapy for RM-NPC patients provides a superior PFS compared to GP alone. Most adverse events were similar between the two arms, but immune-related AEs were more frequent in the toripalimab arm.

NATURE MEDICINE (2021)

Review Immunology

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment

Patrizia Leone et al.

Summary: Hepatocellular carcinoma is a common and deadly cancer around the world. Traditional treatments like surgery, radiotherapy, and targeted therapies have been used, but due to the immune suppressive nature of HCC, immunotherapy with immune checkpoint inhibitors has shown great promise in recent clinical studies.

VACCINES (2021)

Article Oncology

Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.

David J. Pinato et al.

Summary: The study evaluated the effects of trans-arterial chemoembolization (TACE) on T-cell function in patients undergoing surgery and found that TACE is associated with a decrease in immune cell density in tumor tissues and an upregulation of inflammatory pathways. This highlights the pleiotropic effects of TACE in modulating the tumor microenvironment and supports the rationale for combining immunotherapy with TACE.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma

Jinpeng Li et al.

Summary: DEB-TACE has shown significant short-term efficacy in the treatment of primary HCC, reducing complications and extending the interval between TACE treatments. Objective response rates were 78.7%, 71.6%, and 63.2% at 2, 4, and 6 months post-treatment, with disease control rates at 95.3%, 92.1%, and 85.9% respectively.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2021)

Review Infectious Diseases

Epidemiological and etiological variations in hepatocellular carcinoma

Evangelista Sagnelli et al.

INFECTION (2020)

Article Medicine, General & Internal

Transcatheter Arterial Chemoembolisation Combined with Radiofrequency Ablation on Hepatocellular Carcinoma and Levels of Relevant Markers

Jia Feng et al.

JCPSP-Journal of the College of Physicians and Surgeons Pakistan (2020)

Article Gastroenterology & Hepatology

The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma

Shou Wu Lee et al.

JOURNAL OF DIGESTIVE DISEASES (2020)

Review Gastroenterology & Hepatology

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

Di-Yang Xie et al.

HEPATOBILIARY SURGERY AND NUTRITION (2020)

Review Biochemistry & Molecular Biology

Hepatocellular carcinoma: old friends and new tricks

Eunsun Kim et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2020)

Review Biochemistry & Molecular Biology

Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma

Young Chang et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Biochemistry & Molecular Biology

Targeting angiogenesis for liver cancer: Past, present, and future

Xiao-Dong Zhu et al.

GENES & DISEASES (2020)

Review Pharmacology & Pharmacy

Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals

Edward M. Russak et al.

ANNALS OF PHARMACOTHERAPY (2019)

Review Gastroenterology & Hepatology

Disease Burden of Hepatocellular Carcinoma: A Global Perspective

Mehmet Sayiner et al.

DIGESTIVE DISEASES AND SCIENCES (2019)

Article Pharmacology & Pharmacy

Toripalimab: First Global Approval

Susan J. Keam

Review Gastroenterology & Hepatology

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Ju Dong Yang et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

Article Gastroenterology & Hepatology

Epidemiology and Management of Hepatocellular Carcinoma

Laura Kulik et al.

GASTROENTEROLOGY (2019)

Review Biotechnology & Applied Microbiology

Recent developments with immunotherapy for hepatocellular carcinoma

Oliver Waidmann

EXPERT OPINION ON BIOLOGICAL THERAPY (2018)

Review Oncology

DEB-TACE: a standard review

Fabio Melchiorre et al.

FUTURE ONCOLOGY (2018)

Review Medicine, General & Internal

Hepatocellular carcinoma

Alejandro Forner et al.

LANCET (2018)

Article Medical Laboratory Technology

The diagnosis and treatment of hepatocellular carcinoma

Justin Hartke et al.

SEMINARS IN DIAGNOSTIC PATHOLOGY (2017)

Article Gastroenterology & Hepatology

Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system

Kichang Han et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2015)

Article Gastroenterology & Hepatology

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness

Adriana Sergio et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)